Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Japan's Takeda eyes new focus on vaccines after OTC asset sales: CEO

Stock MarketsNov 05, 2020 10:25PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. A Takeda logo is seen in its research hub in Cambridge

By Rocky Swift

TOKYO (Reuters) - Japan's Takeda Pharmaceutical Co (T:4502) is looking at making vaccines a core business after completing asset sales to lower debt following its takeover of Shire Plc (LON:SHP), Chief Executive Christophe Weber said.

Japan's biggest drugmaker by revenue recently completed $10 billion in sales of mostly over-the-counter drug assets to reduce debt after its $59 billion purchase of Shire, saying it would focus on five key business areas.

With a dengue fever vaccine in development and deals to make and distribute COVID-19 vaccines in Japan, the company could add a new pillar to its business lineup, Weber said.

"We are in the vaccines business," Weber told Reuters in an interview. "If the dengue vaccine is successful, yes, it would be a sixth one."

Takeda's current five core businesses are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies.

The company looked into making a COVID-19 vaccine, but determined with its mix of technology and capacity, it was a better fit to work with other developers, Weber said.

Takeda agreed last month to distribute 50 million doses of Moderna Inc's (O:MRNA) COVID-19 vaccine in Japan. That was on top of a previous deal to produce Novavax Inc's (O:NVAX) COVID-19 candidate, aiming to make 250 million doses.

Takeda's dengue vaccine candidate, TAK-003, is on track for regulatory filing in Asia, Latin America, and the European Union by the end of fiscal 2020, the company said last month. The disease is spread by mosquitoes and is estimated to affect 50 million people a year worldwide with 22,000 deaths.

Following the Shire takeover, Takeda reached its asset disposal goal with the sale of its Japanese consumer healthcare business to Blackstone Group (N:BX) for 242 billion yen ($2.31 billion) announced in August.

The company was not eyeing any more major sell offs, Weber said, saying any such deals would be "very marginal."

Japan's Takeda eyes new focus on vaccines after OTC asset sales: CEO
 

Related Articles

Telekom Malaysia signs up for country's 5G trials
Telekom Malaysia signs up for country's 5G trials By Reuters - Dec 04, 2021

KUALA LUMPUR (Reuters) - Telekom Malaysia on Saturday said it will be conducting 5G trials with a state-run agency ahead of a planned roll out of 5G network services this month....

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email